Generalized Myasthenia Gravis

Advancing Care for Patients with gMG

gMG is a rare, chronic autoimmune neuromuscular disorder that disrupts communication between nerves and muscles, leading to muscle weakness that can impact mobility, vision, swallowing, and breathing. The disease is mediated by autoantibodies, most commonly targeting the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), which interfere with neuromuscular transmission.

While several therapies are available, many patients continue to experience persistent symptoms or intolerable side effects.

As a result, there remains a significant unmet need for new therapies that offer durable efficacy, a favorable safety profile, and convenient administration to improve the quality of life for people living with gMG. There are approximately 90,000 people in the United States, 140,000 in Europe, and 29,000 in Japan living with the disease.

Clinical Trials – Telitacicept in Generalized Myasthenia Gravis (gMG)

The RemeMG Phase 3 global study is evaluating the efficacy, safety, and tolerability of telitacicept in patients with generalized myasthenia gravis (gMG).

The ongoing Phase 3 global trial is a randomized, double-blind, placebo-controlled study with an open-label extension.

Objective

To assess the impact of telitacicept on MG-ADL and QMG scores in patients with AChR+ or MuSK+ gMG.

Endpoints

• Primary – MG-ADL change from baseline at Week 24
• Secondary – QMG, MG-QOL15r, responder rates, minimal symptom expression.

Enrollment

~180 patients across North America, Europe, Asia-Pacific.